ALACHUA, FL – January 24, 2014 – AxoGen, Inc. (NASDAQ: AXGN), the only medical products company completely focused on peripheral nerve repair, today announced the acceptance of a scientific presentation on nerve repair at the 2014 International Symposium on Peripheral Nerve Regeneration (ISPNR) 2014 Meeting. The symposium, being held in Torino, Italy, acts as a platform for presenting and discussing new developments in the field of nerve regeneration and tissue engineering and attracts clinicians and researchers from across the globe.
Erick DeVinney, AxoGen’s VP of Clinical and Translational Sciences will give the presentation entitled, “Application of Regenerative Medicine Principles in the Design, Development and Clinical Translation of Process Nerve” on Saturday, January 25 during ISPNR’s Scientific Session.
Stefano Guena, Professor at the University of Torino, Italy, and a member of the ISPNR Organizing Committee commented, “We are excited about the many new approaches to nerve repair being presented at ISPNR 2014. The AxoGen presentation on the scientific principles of nerve regeneration and Avance® Nerve Graft technology helps advance our understanding of the successful clinical applications of processed nerve allograft.”
The conference is organized by the University of Torino and receives funding from the European Union’s 7th Framework Programme which is designed to support research and innovation.
About Avance® Nerve Graft
Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The product provides surgeons a readily-available nerve allograft to repair peripheral nerves damaged by trauma or resected during a surgical procedure.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a regenerative medicine company based in Alachua, Florida. Founded in 2002, AxoGen is the only company to completely focus on peripheral nerve repair. AxoGen’s portfolio of products are available in the United States, Canada and several European countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
AxoGen, Inc.
Greg Freitag, CFO & General Counsel
386.462.6856
InvestorRelations@AxoGenInc.com
www.AxoGenInc.com
Source: AxoGen, Inc.
Help employers find you! Check out all the jobs and post your resume.
